SOMATROPIN (HGH) Hilma Biocare

Somatropin Human Growth Hormone Injection

Somatropin [somatropin (rDNA origin) for injection] is a recombinant form of human growth hormone (hGH) manufactured using recombinant DNA technology. The active protein contains 191 amino acid residues and has a molecular weight of approximately 22,125 daltons. Its amino acid sequence is identical to naturally occurring human growth hormone produced by the pituitary gland.

Unlike older pituitary-derived growth hormone preparations, recombinant somatropin is produced through controlled biotechnology processes. This manufacturing approach allows the hormone to be created without obtaining growth hormone from human pituitary tissue.

Recombinant Human Growth Hormone

Somatropin is classified as a polypeptide hormone. Its molecular structure closely matches endogenous human growth hormone, allowing it to interact with growth hormone receptors in the body.

The finished pharmaceutical product may contain a limited amount of deamidated growth hormone during its approved shelf life. According to product-characterization information, this deamidated form has been studied and retains biological activity. Manufacturing specifications control the permitted amount throughout the product’s expiration period.

The recombinant production process is designed to maintain the identity, purity, and biological characteristics of the active protein. Because somatropin is a protein-based medicine, appropriate preparation, handling, and storage are particularly important for maintaining product integrity.

Pharmaceutical Characteristics

Somatropin for injection is supplied as a pharmaceutical preparation intended for administration according to the instructions provided with the specific product. Presentation, concentration, vial size, cartridge format, diluent requirements, and excipients can vary between manufacturers.

Important product characteristics include:

• Recombinant human growth hormone
• 191-amino-acid polypeptide structure
• Approximate molecular weight of 22.1 kDa
• Amino acid sequence identical to human pituitary growth hormone
• Manufactured using recombinant DNA technology
• Formulated specifically for injectable administration

These specifications distinguish somatropin from unrelated peptide products and other hormone preparations.

How Somatropin Functions

Human growth hormone participates in several physiological processes involving growth, protein metabolism, body composition, and tissue development. Somatropin acts through the same growth hormone receptor system used by naturally produced hGH.

Its clinical use depends on the patient’s diagnosis, age, medical history, laboratory findings, and treatment response. For this reason, treatment decisions should be made by an appropriately qualified healthcare professional rather than being based only on product strength or vial size.

Somatropin products may have approved indications involving specific growth disorders or growth hormone deficiency, but indications are not necessarily identical across every brand, formulation, or country. The prescribing information supplied for the exact product should therefore be used to determine its approved uses.

Product Handling and Storage

As a protein medicine, somatropin requires careful storage. Excessive heat, freezing, vigorous shaking, or improper preparation can affect protein stability. Storage conditions vary by manufacturer and may also change after a vial or cartridge has been reconstituted or first used.

Always follow the storage temperature, refrigeration requirements, light-protection instructions, expiration date, and post-reconstitution limits printed on the original packaging or official prescribing information.

If a product requires mixing with a supplied diluent, only the specified diluent and preparation method should be used. The solution should be checked according to the manufacturer’s instructions before administration. Products showing unexpected discoloration, particles, damaged packaging, or compromised seals should not be used.

Important Safety Information

Somatropin is a prescription medicine and is not suitable for unsupervised use. Treatment normally requires medical assessment and ongoing monitoring because growth hormone can influence glucose metabolism, fluid balance, thyroid function, and other physiological systems.

Patients should inform their healthcare professional about existing medical conditions, other medicines being used, pregnancy or breastfeeding, previous tumors, diabetes, thyroid disorders, or other relevant health concerns before starting therapy.

Side effects and contraindications differ according to the patient’s condition and the specific somatropin formulation. The official patient information leaflet or prescribing information should be reviewed for complete warnings, contraindications, interactions, and adverse reactions.

This Somatropin product should be used only when prescribed and administered in accordance with the instructions provided by a qualified healthcare professional and the manufacturer.